Program
RD06-05
A development code. Also written as “RD06-05 CART Cell Injection” and “RD06-05 CAR-T Cell Injection”.
Its studies are mostly in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Lupus Erythematosus, Systemic · Scleroderma, Systemic, led by Nanjing Bioheng Biotech.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Nanjing Bioheng Biotech | 33 open or running | early phase 1since Jan 9, 2025 | Jan 9, 2025 | Jan 1, 2027early phase 1 · NCT06775912 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 9, 2025First study: early phase 1 study in Scleroderma, SystemicFirst studyNCT06775912 · 18 planned · China
- Sep 23, 2025Early phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07203404 · 96 planned · China
- Apr 7, 2026Early phase 1 study in Lupus Erythematosus, SystemicNCT07596680 · 30 planned · China
Ahead
- Jan 1, 2027Primary completion: early phase 1 study in Scleroderma, SystemicNCT06775912
- Jul 23, 2027Primary completion: early phase 1 study in Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisNCT07203404
- Apr 30, 2028Primary completion: early phase 1 study in Lupus Erythematosus, SystemicNCT07596680
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07596680Lupus Erythematosus, Systemic · China | Early 1 | Not yet recruiting | Apr 30, 2028 | 30 |
| NCT07203404Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · China | Early 1 | Recruiting | Jul 23, 2027 | 96 |
| NCT06775912Scleroderma, Systemic · China | Early 1 | Recruiting | Jan 1, 2027 | 18 |
How it is read
Names in the registry
- “RD06-05 CART Cell Injection”, 2 entries
- “RD06-05 CAR-T Cell Injection”, 1 entry
Codes read as this program: RD0605.
Conditions, from the studies’ own filings
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, 1 study
- Lupus Erythematosus, Systemic, 1 study
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.